Innova Captab Limited · NSE:INNOVACAP
Innova Captab — Q2 FY26 Earnings Presentation
30 slides from Innova Captab's earnings presentation, Nov 7, 2025
Slide 1: Intimation letter to stock exchanges
INNOVA CAPTAB LIMITED Plot No. 320, Industrial Area, Phase-1, Panchkula, Pin-134113, Haryana, India. Phone: +91-172-4194500 07th November, 2025 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, 5th Floor Dalal Street, Mumbai – 400001 Plot No. C/1
Slide 2: Excelling with Passion, Powering Potential
Excelling with Passion Powering Potential Investor Presentation - 7th November 2025
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Innova Captab Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securit
Slide 4: Company Overview
Company Overview
Slide 5: Leading Pharmaceutical Player with Comprehensive Business Model
Leading Pharmaceutical Player with Comprehensive Business Model Robust Financials Preferred CDMO partner for prominent pharmaceutical companies worldwide, with a strong direct (FY25) presence across geographies through our branded generics business Revenues ₹ 1,244 Cr EBITDA 300 + Presence across 60
Slide 6: With State-of-the-Art Manufacturing Facilities
With State-of-the-Art Manufacturing Facilities Key Accreditations 9 Manufacturing Blocks Kathua, Jammu [4 Blocks] 3 Baddi |1 Dehradun |1 Taloja | 4 Jammu Upcoming R&D Baddi, Himachal Pradesh (2 Units) [3 Blocks] Facility in R&D Facility in Baddi, Himachal Pradesh Panchkula, Haryana Dehradun, Uttarak
Slide 7: Journey of Achieving Major Milestones
Journey of Achieving Major Milestones Acquisition of Sharon • Innova Captab began its • Received GMP Certificate for • Acquisition of Sharon, through the journey in 2006 with the cephalosporin products from • Further expanded the G block Corporate Insolvency Resolution Process establishment of first
Slide 8: Regrouping of Business Areas
Regrouping of Business Areas Robust Financials Reorganized into two focused verticals - CDMO and Branded Generics Business w.e.f 1st April 2025 (FY25*) CDMO Sharon Bio-Medicine CDMO Part of International Reorganised Branded Generics Branded Generics Domestic Branded Generics Part of International Br
Slide 9: Q2 & H1 FY26 Performance Highlights
Q2 & H1 FY26 Performance Highlights
Slide 10: MD's Commentary
MD’s Commentary Our strategic initiatives continue to deliver measurable outcomes, as evidenced by YoY revenue growth of 19.5% both in Q2 and H1 FY26 reaching ₹ 380 crores and ₹ 732 crores respectively. We witnessed healthy volume growth, underscoring the sustained demand momentum and operational ef
Slide 11: Q2 & H1FY26 Performance Highlights - Revenue
Q2 & H1FY26 Performance Highlights - Revenue Revenue (₹ Crore) +19.5% 731.9 • Revenue from Operations registered stellar YoY growth of 19.5% 612.5 both in Q2 and H1 FY26 +19.5% • Consistent volume growth reflected strong operational execution 380.4 and fueled revenue growth 318.2 • Exports contribut
Slide 12: Q2 & H1FY26 Performance Highlights - Profitability
Q2 & H1FY26 Performance Highlights - Profitability EBITDA (₹ crore) Margin 16.3% 14.7% 15.7% 15.4% +17% 112.6 +8% 96.2 • Achieved EBITDA of ₹ 56.1 crores in Q2 FY26 and ₹ 112.6 crores in H1FY26, registering YoY growth of 8% and 17%, respectively 51.9 56.1 • EBITDA margin was 14.7% in Q2 FY26 and 15.
Slide 13: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit and Loss (₹ crore) Q2 FY26 Q2 FY25 YoY Growth H1 FY26 H1 FY25 YoY Growth Revenue from Operations 380.4 318.2 19.5% 731.9 612.5 19.5% Other Income 4.2 2.2 8.7 4.3 Total Income 384.6 320.4 20.0% 740.6 616.8 20.1% Cost of Material Consumed 243.6 207.0 464.3 4
Slide 14: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (₹ crore) As on 30th Sept 2025 As on 31st Mar 2025 Equity & Liabilities (₹ crore) As on 30th Sept 2025 As on 31st Mar 2025 Non - Current Assets 878.0 877.3 Total Equity 1,021.1 959.4 Property, plant and equipment 785.5 766.9 Right of use assets 44.1 45.5 Share Capit
Slide 15: Consolidated Cash Flow
Consolidated Cash Flow Particulars (₹ crore) Sept-25 Sept-24 Net Profit Before Tax 81.9 86.1 Adjustments for: Non -Cash Items / Other Investment or Financial Items (28.1) (12.1) Operating profit before working capital changes 110.0 98.3 Changes in working capital (68.0) (52.5) Cash generated from Op
Slide 16: Key Strengths
Key Strengths
Slide 17: Building on Core Strengths, Unlocking Future Growth
Building on Core Strengths, Unlocking Future Growth Extensive Product Offerings, Wider Reach, R&D Centric Organization Stronger Future Comprehensive Business Experienced Promoters and Model Board of Directors Relentless Expansion of Consistent Financial Manufacturing Capabilities: Performance Fuel f
Slide 18: Relentless Expansion of Manufacturing Capabilities (1/3)
Relentless Expansion of Manufacturing Capabilities: Fuel for Sustained Growth (1/3) Our manufacturing Capabilities Jammu Plant Dehradun & Taloja Plant Baddi Plant Expansion through New Greenfield Project Expansion through Inorganic 2025 onwards Acquisition Building blocks for growth 2024 Tablets Cap
Slide 19: Capacity Expansion in Jammu (2/3)
Capacity Expansion in Jammu (2/3) Eligible for following benefits via Central Government's 'New Central Sector Scheme ₹ 480+ crore GST-linked incentive totalling to 300% of investment made in Capital Interest Subvention of 6% per Total Capital Investment eligible plant and machinery annum on loan ag
Slide 20: Growth led by Capacity Expansion (3/3)
Growth led by Capacity Expansion (3/3) Baddi Plant Dehradun & Taloja Plant Jammu Plant 15% - 20% 15% - 20% 20%-30% 70% - 75% 40%-50% 70%-75% 70% - 75% 50% - 55% 50% - 60% FY25 Un-utilized Capacity Optimum Utilization FY25 Un-utilized Capacity Optimum Utilization Commenced Ramp up in Further Optimum
Slide 21: Comprehensive Business Model
Comprehensive Business Model CDMO Services and Products 3,700 + Products • Preferred partner for companies seeking to efficiently deliver high-quality, affordable medicines to market. • Consistently deliver high-quality solutions at scale, while maintaining the 300 + flexibility to tailor offerings
Slide 22: Extensive Product Offerings, Wider Reach, Stronger Future
Extensive Product Offerings, Wider Reach, Stronger Future FY21 FY25 Ongoing development of various formulations will drive Number of Products 1,000 + 3,700 + continued growth in product offerings 119 300+ Focus on consistently adding new clients, with sustained efforts to effectively service the exi
Slide 23: R&D Focused Organisation + R&D Laboratory
R&D Focused Organisation 40 + R&D Laboratory Scientist & Engineers Baddi, Himachal Pradesh Robust Research and Development • Dedicated R&D facility and pilot equipment located in Baddi, Himachal Pradesh, recognized by the DSIR for its in-house R&D work • State-of-the-art facility equipped with a com
Slide 24: Experienced Promoters and Board of Directors
Experienced Promoters and Board of Directors Mr. Manoj Kumar Lohariwala Mr. Vinay Lohariwala Mr. Jayant Vasudeo Rao Mr. Archit Aggarwal Chairman and Whole-Time Director Managing Director Whole-Time Director Non-Executive Non-Independent Director Mr. Sudhir Kumar Bassi Ms. Priyanka Dixit Sibal Mr. Ma
Slide 25: Consistent Financial Performance
Consistent Financial Performance Revenue from Operations EBITDA (₹ crore) PAT (₹ crore) (₹ crore) 13.6% 12.4% 13.3% 15.4% 15.9% 8.4% 8.0% 7.3% 8.7% 10.3% Margin +32% 1,244 1,081 198 926 +37% 167 801 128 +38% 123 99 94 411 64 68 56 35 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 F
Slide 26: Historical Financial Performance
Historical Financial Performance
Slide 27: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit and Loss (₹ crore) FY25 FY24 FY23 FY22 FY21 Revenue from Operations 1,243.7 1,081.3 926.4 800.5 410.7 Other Income 12.0 12.5 9.2 2.9 1.4 Total Revenue 1,255.7 1,093.8 935.6 803.4 412.0 Cost of Materials Consumed 814.1 728.3 691.6 617.9 310.7 Employee Cost
Slide 28: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (₹ crore) FY25 FY24 FY23 FY22 FY21 Equity & Liabilities (₹ crore) FY25 FY24 FY23 FY22 FY21 Non - Current Assets 877.3 741.1 261.9 196.4 99.1 Total Equity 959.4 830.9 276.5 208.6 144.8 Property, plant and equipment 766.9 291.6 150.1 156.6 76.4 Share Capital 57.2 57.2
Slide 29: Consolidated Cash Flow
Consolidated Cash Flow Particulars (₹ crore) FY25 FY24 FY23 FY22 FY21 Net Profit Before Tax 171.0 129.5 91.8 85.7 46.3 Adjustments for: Non -Cash Items / Other Investment or Financial Items (31.3) (37.3) (25.9) (15.3) (9.6) Operating profit before working capital changes 202.3 166.8 117.7 101.0 55.9
Slide 30: Thank You!
Thank You! Innova Captab Limited : Investor Relations Advisor : http://www.sgapl.net/images/sgapl_logo.jpg Strategic Growth Advisors Pvt. Ltd. Innova Captab Ltd. CIN - U74140MH2010PTC204285 CIN – L24246MH2005PLC150371 Ms. Shaily Patwa / Mr. Shrikant Sangani Mr. Lokesh Bhasin/ Mr. Ayush Kumar Garg Em